Herceptin

Was formulated in a landmark publication by Sporn and Todaro [8] in 1980. In the past 20 years, a large body of experimental and clinical data have supported this hypothesis. In this respect, the identification of selective anti-EGFR and antiErbB-2 cancer drugs has been one of the most successful examples of translational research in cancer. Anti-EGFR and anti-erbB-2 blocking monoclonal antibodies MAb ; have been the first in a series of agents with promising preclinical activity, alone and in combination with certain cytotoxic agents or ionizing radiation [9]. A second generation humanized anti-ErbB-2 MAb, trastuzumab Herceptin ; , was the first growth factor receptor-targeted agent approved for clinical use in advanced breast cancer patients whose tumors overexpress ErbB-2; it is used as a single treatment or in combination with paclitaxel [9]. Two anti-EGFR therapeutic approaches have shown promising clinical activity: MAbs and small molecule inhibitors of the EGFR tyrosine kinase enzymatic activity Table 1 ; . Monoclonal antibodies are raised against the extracellular domain of EGFR to block ligand binding and receptor activation. Tyrosine kinase inhibitors TKIs ; prevent the autophosphorylation of the EGFR intracellular tyrosine kinase domain. These molecules are generally reversible competitors of ATP for binding to the intracellular catalytic domain of the EGFR tyrosine kinase. The blockade of EGFR signalling in cancer cells determines not only inhibition of cell proliferation, but also other effects that could be relevant in the clinical setting, such as anti-angiogenic effects by inhibition of tumor cell production of pro-angiogenic growth factors and, possibly, by direct cytotoxicity on endothelial cells in tumor vessels and such as anti-invasive and anti-metastatic effects. These studies have also provided a strong scientific rationale for the development of combined treatments with anti-EGFR targeted agents and conventional anti-cancer therapies, such as chemotherapy, hormonotherapy and radiotherapy.

Year 3 and 4 Phase I II clerkship ; : During clerkship, the student will encounter real world problems in pharmacology and accumulate hands-on experiences. In addition, there are formal teaching sessions provided by various clinical disciplines to complement the clinical experience. The goals of this section include familiarizing the student with: clinical applications of the pharmacological principles and knowledge on therapeutics; frequently used medications in common clinical situations; and approaches for therapeutics trouble shooting.
Table 8. Technology Guide to HER-2 Testing * Immunohistochemistry IHC ; Test code FDA-cleared clinical use 15547 Assess eligibility for trastuzumab Herceptin ; treatment. The `hydrogenosome' at thirty-four years of age and its role in the activity of metronidazole Lindmark, Donald. Biology, Cleveland State University, Cleveland, OH, USA. ATP binding cassette ABC ; transporters and drug efficacy in Cyptosporidium parvum Mead, Jan1, 2; Benitez, Alvaro2; McNair, Nina1. 1. Atlanta VA Medical Center, Decatur, GA, USA. 2. Pediatrics, Emory University, Atlanta, GA, USA. Novel compartmentalization of Cryptosporidium parvum pyruvate: NADP + oxidoreductase within the crystalloid body Ctrnacta, Vlasta2; Stejskal, Frantisek2; Buttle, Karolyn3; Mannella, Carmen3; Hsieh, Chongere3; Marko, Mike3; Wynalek, Jessica4, 1; Keithly, Janet1. 1. Infectious Disease, Wadsworth Center, New York State Department of Health, Albany, NY, USA. 2. Tropical Medicine and Parasitology, Charles University, Prague, Czech Republic. 3. Resource for the Visualization of Biological Complexity, Wadsworth Center, New York State Department of Health, Albany, NY, USA. 4. APHL CDC EID Fellow, Wadsworth Center, New York State Department of Health, Albany, NY, USA. Effects of ion-channel blockers on Plasmodium falciparum viability and their potential use as anti-malarial targets. Martiney, James. Biology and Health Sciences, Pace University, New York, NY, USA. BREAK. Int.Cl.6 C07K 1 08; C07D 209 14; C07C 323 14; C07C 321 12; C07C 317 00; C07C 271 06. Synthesis and use of amino acid fluorides as peptide coupling reagents. RESEARCH CORPORATION TECHNOLOGIES, INC. Table 1. Open Clinical Treatment Trials for Enrollment at HUCC, January 1, 2001, to December 31, 2002 Disease Type Breast Protocol Name A Three Arm Randomized Trial to Compare Adjuvant Adriamycin and Cyclophosphamide Followed by Taxotere AC- T Adriamycin and Taxotere AT Adriamycin, Taxotere, and Cycolphosphamide ATC ; in Breast Cancer Patients with Positive Axillary Lymph Nodes Randomized Trial of Post Mastectomy Radiotherapy in Stage II Breast Cancer in Women with One-Three Positive Axillary Nodes, Phase III A Phase II Study of a Combination of MTA LY231514 ; and Gemcitabine in Patients with Metastatic Breast Cancer A Phase III Study of Doxorubicin-Cyclophasphamide Therapy followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients with Axillary Node-Positive Breast Cancer A Phase III Study of Paclitaxel Via Weekly 1 Hour Infusion Versus Standard 3 House Insusion Every 3 Weeks with Herceptin Trastuzumab ; in the Treatment of Patients with without Her-w neuOverexpressing Breast Cancer Phase III Randomized Study of Adjuvant Immunotherapy With Monoclonal Antibody 17-1A vs. No adjuvant Therapy Following Resection for Stage II Modified Aster-Coller B2 ; Adenocarcinoma of the Colon A Randomized Phase III Trial of Combinations of Oxaliplatin OXAL ; , 5-Fluorouracil and CPT-11 as Initial Treatment of Patients with Advanced Adenocarcinoma of the Colon and Rectum A Phase II Open-Label Multicenter Prospective Trial Evaluating the Toxicities Associated with Subcutaneous Administration of Amifostine for the Prevention of Radiation Induced Toxicities A Phase III Study of Adjuvant Chemotherapy After Section for Patients with T2N0 Stage I Non-small Cell Carcinoma of the Lung Concurrent Carboplatin, Paclitaxel, and Radiation Therapy Versus Induction Carboplatin and Paclitaxel Followed by Concurrent Carboplatin, Paclitaxel and Radiation Therapy For Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase III Trial Phase III Randomized, Double-Blind Study of CAI and Placebo in Patients with Advanced Non-Small Cell Lung Cancer NSCLC ; A Phase II Open-Label, Randomized Trial of Zoledronic Acid with BMS-275291 NSC# 713763 ; in Patients with Hormone Refractory Prostate Cancer Adjuvant Androgen Deprivation versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer Patients Following Radical Prostatectomy-Phase III Research Base NSABP No. of Patients Enrolled at HUCC 2 and hms. The University of Louisville Student Chapter of the ASCE SAME has a new look as they enter the 2006 2007 year. A brand new slate of officers will take over their positions during the summer semester. Those taking office include Randall Strunk as President, Nathan Chappell as Vice President, Clint Mattingly as Treasurer, Josh Mudd as Sergeant at Arms, Adam Mayer as Secretary, Derek Kinder and Stephen Clayton as Editors. Votes were tallied at the annual picnic which was held on Thursday, 13 April. Congratulations to all officers who hope to keep that same momentum going in the ASCE SAME as there has been in the past. Mandy Moore & Stephen Clayton, Editors ASCE SAME Student Chapter.

Q: i've heard that the drug herceptin has shown even more promise than originally thought in treating breast cancer and humalog. Several interesting aspects of breast cancer were covered at this year's American Society of Clinical Oncology meeting. Sentinel lymph node SN ; mapping is now in widespread use, in concert with the general trend toward trying to decrease the morbidity of breast cancer surgery. With every advance, however, comes new challenges, and there was a timely presentation from Giuliano's group addressing the controversial issue of how to interpret the presence of cells in the SN seen only with keratin stains but not by routine hematoxylin and eosin stains. Two abstracts addressed the issue of whether for certain women with invasive breast cancer radiation therapy could be omitted after lumpectomy. Another interesting topic related to hormonal issues in the adjuvant treatment of premenopausal women. An analysis from the ZIPP-TRIAL reported on bone marrow density studies in young women given two years of ovarian suppression in the adjuvant setting: it seems that the loss of bone density may be reversible and, more interestingly, may be prevented with concurrent tamoxifen. Two other presentations looked at the prognostic significance of drug-induced amenorrhea in young women treated with adjuvant chemotherapy and at the efficacy of ovarian suppression during chemotherapy in preserving fertility. In an unpublicized presentation, Mary-Claire King presented very interesting results from the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial suggesting that tamoxifen may be an effective chemopreventive drug for women with BRCA2, but not BRCA1, mutations. Two important presentations re-analyzed the outcome of the pivotal trials using Herceptin to treat metastatic breast cancer and nicely show that FISH analysis of HER-2 overexpression is a more accurate indicator of response to Herceptin than immunohistochemical staining. Finally, there were two interesting presentations related to tamoxifen resistance which may be relevant clinically, pertaining to subsequent raloxifene use and the interaction of the estrogen receptor and EGF receptor pathways, respectively. The Oncologist 2001; 6: 338-346.

Tissues. Fig. 1 shows the distribution of cases according to the tissue or organ predominantly involved with metastatic disease: soft tissue and or lymph node in 7 cases; liver in 6 cases; lung in 6 cases; and bone in 8 cases. Four patients in this series had metachronous bilateral breast cancer, one of which was newly discovered and present at the time of the scintiscan. Interestingly, 3 patients had estrogen receptor ER ; -positive breast cancers with metachronous contralateral ER-negative tumors. Fourteen cases were considered ER negative based on the hormone status of the metastasis or, if unavailable, relying on the results of the primary lesion. All but 2 patients studied were receiving concomitant hormonal therapy, chemotherapy, trastuzumab Herceptin ; , or a combination of these. Two patients were deemed eligible for the 131I dosimetry scan after the initial 99m TcO4- or 123I scans, but only one completed the study. Scintigraphy. The first 7 patients were evaluated scintigraphically with 99mTcO4-. None of these patients was medicated with thyroid hormones. Patient A no. 4 in Table 1 ; showed localization of the tracer in a histologically proven ER-negative, unresectable, ulcerated, axillary recurrence Fig. 2A ; . NIS immunoreactivity was present in 30% of metastatic tumor cells. Both patient and treating physician declined participation in the 131I dosimetry study. The remaining 20 patients were imaged with 123I. Included among these patients were 3 who were receiving systemic therapy and who turned out to have no evidence of metastatic disease on follow-up imaging studies, suggesting that perhaps at the time of their scans little disease, if any, was present. Another patient in this group had longstanding stable bone disease and a new contralateral primary breast tumor. Patient B no. 14 in Table 1 ; had a history of an ERnegative, Her2-neu-positive right lung metastasis with involved regional nodes. On the 123I scan, focal tracer localization was noted in the vicinity of the right pulmonary hilum Fig. 2B ; in conjunction with low thyroid accumulation of 1.4% on handheld probe on T3 for thyroid suppression; 0.088 IU ml TSH ; . Imaging studies performed several months before did not show recurrent lung disease in this region. Accumulation was visualized at 4 h the posterior view only and was not identified on the 24-h scan. Contrastingly, thyroid uptake was noted on the and humira. By use of methodology developed in the Danish Ministry of Transport, first year benefits FYB ; , net present values NPV ; and B C-rates for the conventional CBA have been calculated [2], see Table 1. As shown, project alternative p4 has the highest B C-rate, meaning that this alternative has the highest socio-economic feasibility. Furthermore, as a result of the previous weighting schemes, new calculations are performed to achieve total rate of returns TRR ; comprising both CBA and MCA. As shown, p5 is now the better alternative and p7 is the second best. Alt. p1 p2 p3 Cost in m. DKK 18.30 16.78 18.55 FYB in k. DKK 1884.67 1342.00 840.40 NPV in m. DKK 18.20 9.21 -1.70 49.61 41.96 24.04 B C-rate CBA ; 1.99 1.55 0.91 TRR MCA + CBA ; 2.55 2.65 2.39. The Canadian Organization for Rare Disorders CORD ; would like to thank its Corporate Leaders Forum Members for their support. Through their contributions, CORD is able to continue its invaluable work. Corporate Leader Alexion Pharmaceuticals Celgene Genzyme Canada Inc Pfizer Inc Corporate Supporter Actelion Pharmaceuticals Amgen Canada Bayer BIOTECanada Gilead Sciences Canada Inc INO Therapeutics Merck Frosst Canada Ltd. Novartis Pharmaceuticals Canada Ortho Biotech For more information on becoming a CORD Corporate Forum Member, please visit our website raredisorders . Corporate Friend Amicus Therapeutics Inc. ApoPharma Inc BioMarin Pharmaceutical Inc. Debiovison Inc Hoffmann-La Roche Limited Mark Krueger & Associates Inc. Neurochem Inc Orfagen PTC Therapeutics Inc Rare Disease Therapeutics SHIRE Human Genetic Therapies Sigma-Tau Pharmaceuticals Inc. YM Biosciences Inc and hyaluronan. Was very little pain. Since then, the bleeding is lighter. I absolutely pleased with the results. I used to take 800 milligrams of Motrin when my period started and it still didn't take the pain away. Now, at the most I need a couple of Tylenol for minor cramps right before my period starts, and that's it. I went in for an ultrasound a month after the procedure to see how everything was looking. There wasn't a noticeable change, but since then my abdomen has begun to shrink and I can see a difference. The doctor indicated that there should be a 65 percent reduction in the first three to six months. It's a big relief -- I was so tired of looking pregnant when I'm not. I would recommend this to any woman who has felt the dilemma of what to do about fibroids. Lected under sterile conditions, were immediately transported to the laboratory in ice-cold physiological saline. The tissues were rinsed for 15 sec in 75% alcohol and minced into 0.5-1.0-mm 3 cubes. Approximately 0.5 g of these minces was incubated in a humidified atmosphere for 24 h at 37C in 2.5 to 3.0 ml of phenol red-free Hanks' balanced salt solution containing increasing concentrations of hCG. Then the tissues were homogenized 3-4 times at 4C 5 min each time ; with intermittent rest periods. The homogenates were further subjected to ultrasonic homogenization 2-3 times 1 min each ; . We found that this vigorous homogenization is required for consistent immunoblotting results for CX-43. The protein content in homogenates was determined by the Bradford method, and 5-pg protein aliquots were used for immunoblotting employing a 1: 1500 dilution of CX-43 antibody [12]. The optical densities of CX-43 protein bands were measured by a Pharmacia Piscataway, NJ ; densitometric scanner as previously described [12] and hydralazine.

Major regulatory filings in the first half of 20061 ; Product Actemra Avastin Generic name tocilizumab bevacizumab Indication rheumatoid arthritis; systemic onset juvenile idiopathic arthritis first-line metastatic breast cancer first-line non-squamous, non-small cell lung cancer NSCLC ; advanced or recurrent colorectal cancer Mircera Herceptin MabThera Rituxan formerly C.E.R.A. ; trastuzumab rituximab renal anemia early-stage HER2-positive breast cancer maintenance treatment of follicular non-Hodgkin's lymphoma NHL ; low-grade or follicular CD20-positive NHL Tarceva erlotinib advanced or recurrent NSCLC USA Japan Japan EU, USA, Switzerland EU, USA, Switzerland Switzerland USA, EU USA Country Japan.

To date, over 310, 000 patients with her2-positive breast cancer have been treated with herceptin worldwide and hydrea. A properly prepared prescription for a controlled substance in Schedule II may be transmitted from the prescriber or the prescriber's agent to the pharmacy and the facsimile prescription serves as the original prescription in three 3 ; circumstances. 1. The prescription is to be compounded for the direct administration to a patient by parenteral, intravenous, intramuscular, subcutaneous, or intraspinal infusion. 2. The prescription is for a resident of a Long Term Care Facility LTCF ; . 3. The prescription is for a patient who is a patient of a Medicare or state licensed Hospice agency. The pharmacist will note on the prescription that the patient is a hospice patient and herceptin.
When you order Herceptin * from Aetna Specialty Pharmacy for your Aetna patients, it eliminates the need for you to bill Aetna for the drug; consequently, this reduces your paperwork and administrative burdens. Aetna Specialty Pharmacy handles billing for you! If your office acquires Herceptin from another source and bills Aetna, it is important to note that you must bill with the recommended units for each three-week period. Remember, send prescriptions to Aetna Specialty Pharmacy by simply and hydrocortisone.

Navelbine and with 9 weeks of Herceptin vs. no Herceptin. The implication here is that only 9 weeks of Herceptin may be effective and could reduce cost and cardiotoxicity for patients who are Her2 + . Avastin, a drug that targets a tumor's blood supply, was also the focus of presentations. Dr. Kathy Miller described the results of the phase III, Eastern Cooperative Oncology Group ECOG ; 2100 trial in which patients with locally advanced or metastatic breast cancer received Taxol alone or with Avastin. The overall goal of the trial was to demonstrate increased progression free survival PFS ; . Between 2001 and 2004, researchers found that adding Avastin doubled the overall response rate and increased the PFS by 5 months. The greatest side effect of Avastin has been hypertension, and it doesn't appear to increase the side effects of chemotherapy. Researchers noted response rates were better when the level of vascular endothelial growth factor VEGF ; was greater; however, it is quite difficult to measure VEGF, and there are currently no validated, commercially available tests. Dr. Harold Burstein also presented results of a phase II trial using Avastin with repetitive, low dose metronomic ; chemotherapy. Based on preclinical data and results from a Milan study of oral, low dose CM Cytoxan and Methotrexate ; , researchers added Avastin. The addition of Avastin increased the metabolic activity of the chemotherapy and increased the time to progression by almost 3 months. Based on the results of these trials, some researchers and clinicians are now recommending Avastin be added to first-line chemotherapy for all metastatic breast cancer patients. In fact, I have recently added Avastin to my Abraxane treatments to see if it will improve my response to the chemotherapy. While I hopeful, I don't know whether I agree with the idea of using it with all first-line chemother Continued on page 11. The Reformation: Rational Ethics Denied While Machiavelli advocated the tacit manipulation of society for deliberate [and ultimately virtuous] ends, early Protestant theorists such as Martin Luther and John Calvin regarded ethics as being beyond the rational reach of mankind. The basis for ethical behavior, they said, is that a righteous man will automatically incline towards such behavior, not because it is logically or empirically justified in itself. Salvation attainment of righteousness ; is attainable only through the complete surrender of oneself to Christ. This constituted a rejection of medieval scholasticism, and of the "logical ethics" arguments of Aristotle whom Luther called "this damned, conceited, rascally heathen" ; and Aquinas. The impact of the Protestant Reformation was to remove the rational basis and responsibility for either personal or social ethics, replacing these with the notion of ethics as a suprarational article of religious faith - to be selectively invoked by spokesmen for that religion. Increasing dissatisfaction with such arbitrary proclamations, together with the Catholic Protestant feuds that culminated in the terrible Thirty Years' War, paved the way for the "revolution of reason" that characterized the Enlightenment and hydromorphone.
Since the early 1980s, a series of mouse 225, 528, 425 ; , rat our ICR16, ICR62, ICR64 ; , chimeric IMC-225, also called Erbitux or cetuximab ; , humanized EMD7200, H-R3 ; or fully human anti-EGFR antibodies ABX-EGF, IMC-11F8 ; have been developed against the external i.e. ligand binding ; domain of human EGFR 48-53 ; . Preclinical studies with these antibodies have indicated that they are very effective in 1 ; blocking the binding of EGF family of ligands to the EGFR, 2 ; preventing the ligand-induced phosphorylation of the EGFR and 3 ; inhibiting the growth of human EGFR overexpressing tumours both in culture and as xenografts in athymic mice as a single agent or in combination with cytotoxic drugs or radiotherapy 40, 48-56 ; . The antitumour activities of these antibodies have been shown to be mediated via several mechanisms including down regulation of the EGFR from the cell surface, induction of G1 cell cycle arrest, promotion of apoptosis, inhibition of angiogenesis, and immune destruction via ADCC and CDC 40, 41, 44-55 ; . Clinical trials with several of these anti-EGFR antibodies are currently underway in patients with a wide range of epithelial tumors 50, 52-65 ; . As the mouse anti-EGFR mAb 225, developed by Mendelsohn and colleagues in 1983, was found to be highly immunogenic in cancer patients, a chimeric form of mAb 225 IMC-225 also called cetuximab or Erbitux ; was developed using genetic engineering 50, 51 ; . In addition, as Erbitux contains the antigen binding domain of mouse anti-EGFR mAb 225 and a human IgG1 constant region, it can interact efficiently with the effector arm of the patient's immune system to induce tumour killing via ADCC 50, 51 ; . In November 2004, the USA Food and Drug Administration approved Erbitux for the treatment of metastatic colorectal cancer patients whose tumours overexpress the EGFR 60, 61 ; . Erbitux has been approved for use in combination with irinotecan, in the treatment of EGFR overexpressing metastatic colorectal cancer patients who are unresponsive to irinotecan-based chemotherapy, or as a single agent in patients who are intolerant to irinotecan-based chemotherapy 66 ; . The FDA approval of Erbitux was based on the results of a Phase II clinical trial in which the effect of Erbitux was investigated as a single agent or in combination with irinotecan in 329 patients with EGFR expressing metastatic colorectal cancer refractory to irinotecan-based chemotherapy. The combination treatment of Erbitux and Irinotecan n 218 ; resulted in an objective response rate of 23% and a median time to progression of 4.1 months. When used as a single agent, Erbitux showed a tumour response rate of 11%, a median duration of response of 4.2 months and a median time to disease progression of 1.5 months 60, 61, 66 ; . Clinical trials with Erbitux are currently underway in patients with other types of epithelial tumours including those with lung, head and neck or pancreatic cancer 56, 62 ; . Despite an improved response rate and increased survival of several months, treatment of colorectal cancer patients with Erbitus is currently very expensive. An estimated cost of treatment with Erbirtux with a loading dose of 450 mg m2 in the first week and followed by weekly dose of 250 mg m2 per patient for an eight week duration is around , 300 4 ; . In addition, no clear association has so far been found between the expression of EGFR and the response to therapy with anti-EGFR antibody. This is in contrast to the correlation between the expression of HER-2 antigen and response to therapy with anti-HER-2 antibody Herceptin see below, 55, 60 ; . In several experimental studies, coexpression of other growth factor receptors e.g. IGF-IR ; or mutated forms of the EGFR e.g and hms.